Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination tivozanib and nivolumab in for renal cell carcinoma (RCC) in the TiNivo-2 study ...
The most common combination regimen was MTX plus a TNF inhibitor, followed by MTX plus an IL-23 inhibitor and then MTX plus an IL-17 inhibitor. A total of 7230 AEs were reported, including 680 SAEs (9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results